October 04, 2017

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs

Read More
September 26, 2017

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Read More
September 20, 2017

Selexis SA, Spinomix SA and the University of Lausanne Publish Novel, High-Throughput Technology Process for Isolation of High Secretion CHO Cell Clones

Read More
September 05, 2017

Selexis to Participate at Several Upcoming Industry Conferences

Read More
June 27, 2017

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Read More
June 14, 2017

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

Read More
June 12, 2017

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

Read More
May 30, 2017

Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program

Read More
May 23, 2017

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Read More
May 11, 2017

Selexis SA Opens New World-Class Laboratory Facility and Corporate Headquarters in Geneva, Switzerland

Read More
March 20, 2017

Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic

Read More
March 14, 2017

Selexis Announces Participation at Several Upcoming Industry Conferences

Read More
February 21, 2017

Selexis to Develop Cell Lines for Three Sanofi Biologics Programs Using Selexis SUREtechnology Platform™

Read More